Used in the treatment and prevention of Clostridioides difficile infection (CDI), particularly in high-risk patients. Neutralizes toxin A produced by C. difficile, reducing damage to the intestinal lining and preventing severe diarrhea and colitis. Often administered in combination with other anti-toxin antibodies for enhanced protection. Investigated for use in recurrent CDI cases and as part of passive immunization strategies in clinical settings.